Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Matrixin family protein | 0.0137 | 0 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.1287 | 1 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.1287 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0491 | 0.3077 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0164 | 0.0237 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0491 | 0.3077 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0491 | 0.3077 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.1287 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.1287 | 1 | 0.5 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0228 | 0.0786 | 0.5 |
Onchocerca volvulus | Matrilysin homolog | 0.0164 | 0.0237 | 0.5 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0228 | 0.0786 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0491 | 0.3077 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0491 | 0.3077 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0491 | 0.3077 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0491 | 0.3077 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.1287 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.1287 | 1 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.1287 | 1 | 0.5 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0164 | 0.0237 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.1287 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.